>
Powered by

-Agilent Technologies Introduces Postnatal Assay for Detection of Genetic Anomalies

SANTA CLARA, Calif-Agilent Technologies Inc. (NYSE: A) has introduced its first comparative genomic hybridization (CGH) assay for diagnostic use: the GenetiSure Dx Postnatal Assay.

This assay will enable clinical geneticists to detect genetic anomalies earlier and more accurately than traditional methods can.

Such anomalies have been associated with developmental delay, intellectual disability, autism, congenital irregularities and dysmorphic features in children and adults.

Th

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox